MEDNAX (MD) Earns Neutral Rating from Mizuho
MEDNAX (NYSE:MD)‘s stock had its “neutral” rating reissued by stock analysts at Mizuho in a report issued on Friday, Marketbeat reports. They presently have a $53.00 price target on the stock, up from their prior price target of $49.00. Mizuho’s price objective suggests a potential downside of 2.00% from the company’s current price.
A number of other equities research analysts have also recently weighed in on MD. Jefferies Group set a $50.00 price target on MEDNAX and gave the company a “hold” rating in a research note on Tuesday, February 6th. Robert W. Baird increased their price target on MEDNAX from $48.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday. Stephens set a $62.00 price target on MEDNAX and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus reaffirmed a “hold” rating and issued a $56.00 price objective on shares of MEDNAX in a report on Wednesday, January 24th. Finally, Zacks Investment Research raised MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the stock. MEDNAX currently has an average rating of “Hold” and an average target price of $54.92.
MEDNAX (NYSE:MD) traded up $0.14 on Friday, reaching $54.08. The company had a trading volume of 436,484 shares, compared to its average volume of 921,034. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 0.60. The company has a market cap of $5,051.76, a PE ratio of 15.63, a PEG ratio of 1.47 and a beta of 0.31.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 2.40% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Thompson Siegel & Walmsley LLC grew its holdings in shares of MEDNAX by 19.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock worth $112,065,000 after purchasing an additional 428,184 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of MEDNAX by 4.8% during the 3rd quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock worth $100,198,000 after purchasing an additional 106,883 shares in the last quarter. Earnest Partners LLC grew its holdings in shares of MEDNAX by 0.7% during the 3rd quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock worth $64,437,000 after purchasing an additional 11,037 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of MEDNAX by 25.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,424,574 shares of the company’s stock worth $61,428,000 after purchasing an additional 293,011 shares in the last quarter. Finally, Pzena Investment Management LLC acquired a new stake in shares of MEDNAX during the 4th quarter worth $51,411,000. 95.22% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “MEDNAX (MD) Earns Neutral Rating from Mizuho” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/02/11/mizuho-reiterates-53-00-price-target-for-mednax-md.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.